Business Context and Reporting Period
Company: Takeda Pharmaceutical Company Limited
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Date: May 27, 2020
Reporting Period: Fiscal Year ended March 31, 2020 (April 1, 2019 – March 31, 2020)
Purpose: Disclosure of the Notice of Convocation for the 144th Ordinary General Meeting of Shareholders, including the Business Report, Consolidated Statement of Changes in Equity, and Notes to Financial Statements.
Key Financial Metrics
Consolidated Results (IFRS):
- Net Profit for the Year: 44,241 million JPY
- Comprehensive Income (Loss): (199,569) million JPY (driven by significant Other Comprehensive Loss)
- Basic Earnings Per Share: 28.41 JPY
- Equity Attributable to Owners: 4,723,483 million JPY (as of March 31, 2020)
- Dividends Paid: 282,693 million JPY (90 JPY per share)
- Dividends Proposed: 141,858 million JPY (90 JPY per share) for the fiscal year ended March 31, 2020
Unconsolidated Results (Parent Company):
- Net Income: 130,626 million JPY
- Net Assets Per Share: 2,919.21 JPY
Debt and Liquidity:
- Bonds (Carrying Amount): 3,204,965 million JPY
- Long-term Loans (Carrying Amount): 1,883,325 million JPY
- Lease Liabilities (IFRS 16 adoption): 217,325 million JPY recognized at transition (April 1, 2019)
Material Changes and Accounting Adjustments
- IFRS 16 Adoption: Takeda adopted IFRS 16 (Leases) on April 1, 2019, using the modified retrospective approach. This resulted in the recognition of lease liabilities of 217,325 million JPY and Right-of-Use (ROU) assets of 199,256 million JPY. The cumulative effect was recognized in retained earnings.
- Shire Acquisition Integration: The company completed the purchase price allocation for the Shire acquisition. Retained earnings and exchange differences were retrospectively adjusted. Restructuring expenses totaled 181,040 million JPY, with 135,385 million JPY attributed to Shire integration costs.
- Income Tax Benefit: A significant income tax benefit of 105,044 million JPY was recorded, primarily due to lower pre-tax earnings and a non-cash deferred tax benefit of 94,611 million JPY resulting from tax reform in Switzerland.
- Other Comprehensive Loss: A loss of 243,810 million JPY was recorded in other comprehensive income, significantly impacting total comprehensive income.
Outlook, Risks, and Contingencies
Management Commentary and Governance:
- Governance Structure: Takeda operates as a "Company with Audit and Supervisory Committee" (ASC). The Board consists of 16 members (11 External Directors). The Audit and Supervisory Committee held 11 meetings during the fiscal year.
- Risk Management: The company established a Global Crisis Management Committee on COVID-19, issuing guidance on travel restrictions and remote working. Cybersecurity investments were increased, and insurance coverage was obtained for significant cybersecurity events.
Material Risks and Litigation:
- ACTOS Product Liability: Takeda has paid 2.4 billion USD (approx. 288 billion JPY) into a settlement fund for bladder cancer claims. Economic loss cases and state lawsuits (Mississippi, Louisiana) remain active or in appeal. Aggregate provisions for legal disputes were 49,711 million JPY as of March 31, 2020.
- PPI Product Liability: Approximately 6,400 lawsuits filed in the U.S. alleging kidney injuries from PREVACID and DEXILANT. Similar class actions are pending in Canada.
- Intellectual Property:
- TRINTELLIX: Patent infringement lawsuits filed against 16 generic companies; trial scheduled for October 2020.
- ADYNOVATE: Jury awarded Bayer 155.2 million USD in damages; Takeda has appealed.
- ENTYVIO: Settled patent disputes with Roche in December 2019; impact deemed not material.
- Regulatory Investigations:
- DOJ Investigations: Received Civil Investigative Demands (CIDs) in February 2020 regarding potential off-label promotion of TRINTELLIX and potential kickbacks related to subcutaneous IG products (Cuvitru, HyQvia, Gammaguard).
- Patient Assistance Programs: Cooperating with DOJ investigations into ARIAD and Shire patient assistance programs and interactions with 501(c)(3) organizations.
- Irish Tax Assessment: Appealing a 398 million EUR tax assessment from the Irish Revenue Authority regarding a break fee from AbbVie.
Subsequent Events:
- Divestiture: On April 24, 2020, Takeda agreed to divest a portfolio of OTC and prescription products in Europe and two manufacturing sites (Denmark, Poland) to Orifarm Group for up to 670 million USD. Closing expected by March 31, 2021.
Investor Verification Checklist
- ACTOS Litigation Exposure: Verify the status of pending economic loss cases and state lawsuits, and assess if current provisions (49,711 million JPY) are sufficient given the history of settlements.
- DOJ Investigations: Monitor the outcome of the February 2020 Civil Investigative Demands regarding TRINTELLIX and subcutaneous IG products for potential fines or settlements.
- Shire Integration Costs: Review the trajectory of integration costs (135,385 million JPY in FY2020) to ensure they align with the strategic roadmap and do not erode future margins.
- Patent Cliff Risks: Track the October 2020 trial date for TRINTELLIX and the status of ADYNOVATE appeals, as loss of patent protection could materially impact future revenue.
- Divestiture Impact: Confirm the final terms and closing date of the Orifarm transaction to understand the impact on future European revenue streams.